Trending
How to Read a Peptide COA: HPLC, Mass Spec and Lab Buying
2026-10-29 · 3 min read
A peptide certificate of analysis, or COA, should help a laboratory evaluate a specific batch—not simply advertise a purity percentage. Understanding what HPLC and mass spectrometry measure, and what they leave unanswered, makes research purchasing more informed. This guide explains how to review lot-specific documentation, spot gaps in testing, and compare research peptide suppliers without mistaking analytical results for proof of suitability for human or animal use.
1. Start With the Lot Number and Report Details
Before comparing analytical results, confirm that the COA identifies the material you intend to purchase. Look for the compound name or product code, batch or lot number, testing laboratory, report date, and methods used. The lot number on the report should match the lot supplied. A report for a different batch does not establish the quality of the material in your shipment.
Distinguish a supplier-created summary from an original third-party laboratory report. Independent testing can strengthen a quality review, but its value depends on sample traceability and the scope of analysis. Ask who submitted the sample, how it was identified, and whether the underlying report or supporting analytical data are available. A laboratory logo alone does not establish independent sampling or batch-wide consistency.
2. Understand What HPLC Purity Actually Means
High-performance liquid chromatography, or HPLC, separates sample components under specified conditions. A chromatogram displays detector response over time, with peaks representing components that the method can distinguish. When purity is reported by peak-area normalization, the main peak's integrated area is compared with the total integrated area included in the calculation.
That percentage is not automatically the percentage of peptide by weight in the vial. Water, counterions, residual solvents, and components that respond poorly to the detector may not be represented adequately. Co-eluting impurities can also complicate interpretation. Review the method, detection wavelength, integration approach, and chromatogram when available; a headline purity value cannot replace those details.
HPLC purity also does not establish peptide quantity or biological activity. A separate validated quantitative assay is needed to support a content claim, while functional testing addresses a different question. Treat chromatographic purity, peptide content, and functional performance as separate attributes rather than interchangeable measures.
3. Use Mass Spectrometry to Assess Identity
Mass spectrometry, often abbreviated MS, measures mass-to-charge ratios. Peptide reports may compare a measured or deconvoluted mass with the expected molecular mass. Agreement supports identity, especially when interpreted alongside chromatography and appropriate reference information. Check that the expected value corresponds to the intended peptide and its specified chemical modifications.
An intact-mass match alone does not prove every aspect of a peptide's structure. Some sequence variants or structural differences cannot be resolved from that result alone. Depending on the research question, additional characterization such as tandem mass spectrometry or other orthogonal methods may be appropriate. Mass spectrometry also does not independently establish sterility, endotoxin levels, or the amount of peptide in each vial.
4. Match the Testing Scope to the Research
A COA is a record of specified tests, not a universal quality guarantee. Determine which attributes matter to the planned laboratory work before purchasing. Depending on the experimental system, relevant questions may include identity, chromatographic purity, quantitative content, solubility, residual solvents, water content, or endotoxin levels. If an attribute is not reported, do not assume it was tested or passed.
Testing requirements should follow the laboratory's protocol and risk assessment. For example, endotoxin contamination can interfere with some cell-based experiments, while uncertainty about peptide content can affect concentration calculations. When a report lacks necessary information, request supplemental documentation or arrange appropriate incoming-material testing rather than extrapolating from HPLC and MS results.
5. Compare Research Kit Suppliers on Documentation and Cost
Compare suppliers using the same checklist: matching lot numbers, accessible third-party reports, clearly defined analytical methods, and transparent purchasing terms. Keep the COA with your receiving records so that experiments remain traceable to the material used. A US supplier address does not, by itself, establish US manufacture; request separate origin documentation if manufacturing location is a procurement requirement.
Wholesale American Peptides supplies research peptides in 10-vial kits with a one-kit minimum and a third-party COA per lot. Volume discounts are 5% at two kits, 7% at three kits, 12% at five kits, and 20% at ten kits. Shipping is flat-rate $70 for 2-day air, with free shipping on orders over $750. Evaluate these terms alongside the documentation needed for your laboratory—not as a substitute for analytical review.
All products are for research use only, not for human or animal administration. A COA documents analytical findings within the scope of the reported methods; it does not establish clinical safety, treatment efficacy, or suitability for administration.
Frequently asked
- Does high HPLC purity mean a vial contains the labeled peptide amount?
- No. HPLC peak-area purity describes the relative detector response of integrated components under a particular method. Establishing peptide content requires an appropriate quantitative assay; it cannot be inferred from purity alone.
- Why should a peptide COA include both HPLC and mass spectrometry?
- They provide complementary information. HPLC evaluates chromatographic separation and purity under defined conditions, while mass spectrometry provides molecular-mass information that supports identity. Neither test answers every quality question.
- Does third-party testing prove that every vial was tested?
- No. A third-party report generally describes the submitted sample. Ask about the sampling plan and lot traceability before drawing conclusions about vial-to-vial consistency or the entire batch.
- Does a peptide COA prove sterility or low endotoxin levels?
- Only if the relevant tests and results are explicitly included. HPLC purity and mass spectrometry do not establish either attribute. Sterility and endotoxin testing are separate evaluations.